Navigation Links
GeneNews appoints Patrick Terry as lead strategic advisor for U.S. commercialization of ColonSentry(TM)

TORONTO, Oct. 15 /PRNewswire-FirstCall/ - GeneNews Limited (TSX: GEN), a company focused on developing blood-based biomarker tests for the early detection of diseases and personalized health management, today announced that it has appointed Patrick Terry as its lead strategic advisor for the U.S. commercial launch of ColonSentry(TM), the world's fist blood-based test to determine a person's current risk for colorectal cancer. Mr. Terry is one of the co-founders of Genomic Health, a leading molecular diagnostics company.

"Having co-founded one of the most successful molecular diagnostic companies in the U.S., Mr. Terry is the ideal individual to advise GeneNews on its U.S. commercialization strategy," said Dr. Heiner Dreismann, Interim CEO and Lead Director of GeneNews. "Mr. Terry is a pioneer in the field of personalized medicine. His experience growing Genomic Health from a start up to a company with $64 million in revenues will be invaluable as we prepare for U.S. commercialization of our ColonSentry(TM) test in 2009." The Company launched its lead product, the ColonSentry test, in Canada earlier this year.

Mr. Terry is the co-founder and former Director of Consumer Advocacy & Governmental Affairs at Genomic Health. He is also co-founder and former President of the International Genetic Alliance, which focuses on empowering problem solving by networking the consumer movement, centers of excellence, and high technology with patient communities around the world. Mr. Terry has published dozens of peer-reviewed scientific papers, articles, and book chapters in the field of genetics, personalized medicine, and biomedical research. Some of his activities include leadership positions on numerous trade associations, professional societies, corporate boards, and he also sits on a number of U.S. federal advisory bodies.

About GeneNews


GeneNews is focused on the application of functional genomics to enable early diagnosis and personalized therapeutic intervention based on disease-specific biomarkers. The Company has developed a novel approach, the Sentinel Principle(TM), to detect and stage virtually any disease or medical condition from a simple blood sample. GeneNews is currently applying the Sentinel Principle(TM) in major areas with unmet clinical needs such as cancer, arthritis, cardiovascular disease and neurological disorders. For more information on GeneNews, visit

This press release contains forward-looking statements, which reflect the Company's current expectations regarding future events. The forward-looking statements involve risks and uncertainties. Actual events could differ materially from those projected herein. Investors should consult the Company's ongoing quarterly filings and annual reports for additional information on risks and uncertainties relating to these forward-looking statements. The reader is cautioned not to rely on these forward-looking statements. The Company disclaims any obligation to update these forward-looking statements.

SOURCE GeneNews Limited
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. GeneNews Announces Second Quarter Results
2. GeneNews launches worlds first blood test for colorectal cancer screening
3. GeneNews announces management changes to support commercialization of ColonSentry(TM)
4. Genenews adds two members to its Board of Directors
5. GeneNews Announces First Quarter Results
6. GeneNews reports positive results from validation study of colorectal cancer biomarkers in late-breaking abstract at AACR
7. GeneNews announces 2007 year end results
8. GeneNews selected to present late-breaking abstract at AACR Annual Meeting
9. GeneNews receives ISO 13485 accreditation
10. GeneNews initiates patient sample accrual for validation studies of colon cancer blood test
11. GeneNews Chief Scientist Dr. C.C. Liew co-editor of new genomics reference book
Post Your Comments:
(Date:10/11/2017)... ... 11, 2017 , ... ComplianceOnline’s Medical Device Summit is back for its 4th ... in San Francisco, CA. The Summit brings together current and former FDA office bearers, ... and government officials from around the world to address key issues in device compliance, ...
(Date:10/11/2017)... ... October 11, 2017 , ... ... implantation and pregnancy rates in frozen and fresh in vitro fertilization (IVF) ... and maternal age to IVF success. , After comparing the results from the ...
(Date:10/10/2017)... Poway, California (PRWEB) , ... October 10, 2017 , ... ... afternoon speaking at his local San Diego Rotary Club. The event ... San Diego, CA and had 300+ attendees. Dr. Harman, DVM, MPVM was joined ...
(Date:10/9/2017)... , Oct. 9, 2017  BioTech Holdings ... mechanism by which its ProCell stem cell therapy ... limb ischemia.  The Company, demonstrated that treatment with ... of limbs saved as compared to standard bone ... molecule HGF resulted in reduction of therapeutic effect.  ...
Breaking Biology Technology:
(Date:7/20/2017)... (NYSE: DAL ) customers now can use fingerprints instead of ... Airport (DCA). ... Delta launches biometrics to board aircraft at Reagan Washington National Airport ... Delta,s biometric boarding pass experience that launched in May ... boarding process to allow eligible Delta SkyMiles Members who are enrolled in ...
(Date:5/16/2017)... -- Veratad Technologies, LLC ( ), an innovative and ... solutions, announced today they will participate as a sponsor ... May 17, 2017, in Washington D.C.,s ... Identity impacts the lives of billions of ... digital world, defining identity is critical to nearly every ...
(Date:4/18/2017)... SUNNYVALE, Calif. , April 18, 2017  Socionext Inc., a ... prototype of a media edge server, the M820, which features the ... face recognition software provided by Tera Probe, Inc., will be showcased ... and at the NAB show at the Las Vegas ... ...
Breaking Biology News(10 mins):